Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 221-227

  Landesman Milo, Dalit ^a   Goldsmith, Meir ^a   Leviatan Ben Arye, Shani ^a   Witenberg, Bruria ^a   Brown, Emily ^a,b   Leibovitch, Sigalit ^c   Azriel, Shalhevet ^c   Tabak, Sarit ^c   Morad, Vered ^c   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c Harlan Biotech Israel Limited   (Israel)

Author keywords

Cancer cells; Hyaluronan; Immune response; Lipid based nanoparticles; RNAi

Indexed keywords

CHOLESTEROL; CYTOKINE; GLYCOSAMINOGLYCAN; HYALURONIC ACID; LIPID BASED NANOPARTICLE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PHOSPHOLIPID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA INTERFERENCE; TARGET CELL;

HUMANS; HYALURONIC ACID; LIPIDS; NANOPARTICLES; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84878263116     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.024     Document Type: Article

References (36)

1. Castanotto D., Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457:426-433.
2. Peer D., Lieberman J. Special delivery: targeted therapy with small RNAs. Gene. Ther. 2011, 18:1127-1133.
3. Behlke M.A. Progress towards in vivo use of siRNAs. Mol. Ther. 2006, 13:644-670.
4. Buyens K., De Smedt S.C., Braeckmans K., Demeester J., Peeters L., van Grunsven L.A., de Mollerat du Jeu X., Sawant R., Torchilin V., Farkasova K., Ogris M., Sanders N.N. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J. Control Release 2012, 158:362-370.
5. Huang L., Liu Y. In vivo delivery of RNAi with lipid-based nanoparticles. Annu. Rev. Biomed. Eng 2011, 13:507-530.
6. Zhang S., Zhao B., Jiang H., Wang B., Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Control Release 2007, 123:1-10.
7. Karmali P.P., Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin. Drug Deliv. 2011, 8:343-357.
8. Senior J.H., Trimble K.R., Maskiewicz R. Interaction of positively-charged liposomes with blood: implications for their application in vivo. Biochim. Biophys. Acta 1991, 1070:173-179.
9. Kedmi R., Ben-Arie N., Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 2010, 31:6867-6875.
10. Lonez C., Lensink M.F., Vandenbranden M., Ruysschaert J.M. Cationic lipids activate cellular cascades. Which receptors are involved?. Biochim. Biophys. Acta 2009, 1790:425-430.
11. Solmesky L.J., Shuman M., Goldsmith M., Weil M., Peer D. Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach. Nanotechnology 2011, 22:494016.
12. Lapcik L.J.a.L., Lapcik L., De Smedt S., Demeester J., Chabrecek P. Hyaluronan: preparation, structure, properties, and applications. Chem. Rev. 1998, 98:2663-2684.
13. O'Regan M., Martini I., Crescenzi F., De Luca C., Lansing M. Molecular mechanisms and genetics of hyaluronan biosynthesis. Int. J. Biol. Macromol. 1994, 16:283-286.
14. Naor D., Wallach-Dayan S.B., Zahalka M.A., Sionov R.V. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin. Cancer Biol. 2008, 18:260-267.
15. Peer D., Florentin A., Margalit R. Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim. Biophys. Acta 2003, 1612:76-82.
16. Eliaz R.E., Szoka F.C. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001, 61:2592-2601.
17. Peer D., Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia, New York, N.Y. 2004, 6:343-353.
18. Peer D., Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer 2004, 108:780-789.
19. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science, New York, N.Y. 2008, 319:627-630.
20. Yerushalmi N., Arad A., Margalit R. Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch. Biochem. Biophys. 1994, 313:267-273.
21. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
22. Mizrahy S., Raz S.R., Hasgaard M., Liu H., Soffer-Tsur N., Cohen K., Dvash R., Landsman-Milo D., Bremer M.G., Moghimi S.M., Peer D. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J. Control Release 2011, 156:231-238.
23. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V., Vaish N., Zinnen S., Vargeese C., Bowman K., Shaffer C.S., Jeffs L.B., Judge A., MacLachlan I., Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 2005, 23:1002-1007.
24. Leuschner F., Dutta P., Gorbatov R., Novobrantseva T.I., Donahoe J.S., Courties G., Lee K.M., Kim J.I., Markmann J.F., Marinelli B., Panizzi P., Lee W.W., Iwamoto Y., Milstein S., Epstein-Barash H., Cantley W., Wong J., Cortez-Retamozo V., Newton A., Love K., Libby P., Pittet M.J., Swirski F.K., Koteliansky V., Langer R., Weissleder R., Anderson D.G., Nahrendorf M. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 2011, 29:1005-1010.
25. Goldsmith M., Mizrahy S., Peer D. Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine (Lond) 2011, 6:1771-1785.
26. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
27. Landesman-Milo D., Peer D. Altering the immune response with lipid-based nanoparticles. J. Control Release 2012, 161:600-608.
28. Shim M.S., Kwon Y.J. Efficient and targeted delivery of siRNA in vivo. FEBS J. 2010, 277:4814-4827.
29. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr. Opin. Biotechnol. 2011, 22(4):492-501.
30. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
31. Li W., Szoka F.C. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 2007, 24:438-449.
32. Filion M.C., Phillips N.C. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim. Biophys. Acta 1997, 1329:345-356.
33. Szebeni J., Muggia F., Gabizon A., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 2011, 63:1020-1030.
34. Laurent T.C., Fraser J.R. Hyaluronan. FASEB J. 1992, 6:2397-2404.
35. Platt V.M., Szoka F.C. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm. 2008, 5:474-486.
36. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur. J. Cancer 2010, 46:1271-1277.